Botanix Pharmaceuticals Shares Phase 2 Results for BTX 1503

- October 29th, 2019

Botanix Pharmaceuticals, a medical dermatology company, released new key findings for a Phase 2 study of its BTX 1503 product.

Botanix Pharmaceuticals (ASX:BOT), a medical dermatology company, released new key findings for a Phase 2 study of its BTX 1503 product.

As quoted in the press release:

Key highlights

• All doses of BTX 1503 were very safe – no serious adverse events or treatment related discontinuations while achieving positive effects on acne lesion reductions
• BTX 1503 as a once daily application had the best performance, which from a compliance and commercial perspective, is the ideal dosing regime
• A strong and consistent impact on inflammatory lesions was seen across the entire study with even greater non-inflammatory lesion reductions
• Australian sites showed clear separation of BTX 1503 5 percent once a day vs vehicle – 40.8 percent vs 26.4 percent for inflammatory and 38.1 percent vs 5.1 percent for non-inflammatory lesions
• Patients in the USA that received vehicle had a high vehicle response which skewed the primary endpoint

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Get the latest Australia Investing stock information

Get the latest information about companies associated with Australia Investing Delivered directly to your inbox.

Australia Investing

Select None
Select All

Leave a Reply

Your email address will not be published. Required fields are marked *